NegEnt-Your Sub Title Here


  Cannabidiol-based Neurotherapy in Psychiatry

NegEnt is a product for aromatherapy based on CBD crystals, 99% pure plus 1% of terpenes, derived from dry inflorescences of cannabis light; the name and logo have been developed and patented by Prof. Tullio Scrimali.

The name NegEnt is an abbreviation of Negative Entropy that, in turn, refers to the innovative and, in some ways revolutionary, model for schizophrenia therapy, developed by Prof. Tullio Scrimali (Scrimali T .: Entropy of Mind and Negative Entropy. A Cognitive and Complex Approach to Schizophrenia and its Therapy. Karnac Books, London, 2008).

Schizophrenia and, in general, psychological disorders, have been defined by Tullio Scrimali as Entropy of the Mind, with reference to Thermodynamics, to indicate a disorder of the brain and the mind (therefore any psychiatric disorder). Any treatment in psychiatry must aim, from this perspective, be it pharmacological, psychotherapeutic or rehabilitative, to promote a condition of Negative Entropy.

From this premise comes the choice of the term Negative Entropy for the psychotherapeutic and rehabilitative protocol, developed by Scrimali, to treat schizophrenia and NegEnt, a new cannabidiolic medication, to treat mental disorders.

Contrary to what the name might suggest, Aromatherapy involves the use of essential substances, of vegetable origin, which can be introduced into the body, not only by smelling, but also through the skin, by mouth and inhalation.

NegEnt can be introduced into the body either by inhalation (using a dedicated portable vapouriser) or by ingestion.

It will be offered in a pack of 30 capsules each containing about 100 mg of CBD crystals, with a purity of 99% with 1% of terpenes.

The gastroresistant capsules should be taken preferably on an empty stomach, before meals. Also planned is a pack of 30 capsules each containing 50 mg of cannabidiol crystals.

If you want to use the vaporisation method, the capsules must be opened and the CBD content poured into the burner of a dedicated vapouriser.

The health properties of NegEnt, which are extensively documented in the literature and by specific research carried out by Prof. Tullio Scrimali at the ALETEIA Clinical Center and at the ALETEIA Institute for Medical Cannabis, are mainly attributable to the cannabidiol molecule.

From a marketing point of view, NegEnt falls within the following regulatory framework in Italy.

Regulated cultivation of Cannabis with low THC content and high Cannabidiol content, commonly referred to as "cannabis light";

Current free sale, also via Internet, of CBD crystals;

Free sale of aromatherapy preparations;

Aromatherapy is part of the scientific matter named Naturopathy, currently an unregulated discipline.

NegEnt can be used in psychiatry as a tranquiliser, a neuroleptic and as a mood stabiliser. The anti-inflammatory, pro-metabolic, anti-degenerative and pharmacodynamic characteristics make NegEnt also an excellent neurotrophic product that can improve brain efficiency, as well as promote a better development of the brain in the developmental age or curb decay in neurocognitive disorders and in brain aging.

At the ALETEIA Clinical Centre, Prof. Tullio Scrimali is conducting clinical research on the usefulness of NegEnt in Psychiatry, for the treatment of Anxiety Disorders, Schizophrenia, Depression, Bipolar Disorder, Post-Traumatic Stress Disorder, in Anorexia and Substance Dependencies, Neurodevelopment Disorders (especially those on the autistic spectrum) and in Neurocognitive Disorders.

The initial results of this original research by Prof. Tullio Scrimali are very encouraging and will be published shortly.

On the usefulness of Cannabidiol in Psychiatry, on its exceptional tolerability and on the absence of any side effects, there is a wide and authoritative, although still little known, scientific literature. To view it, you can look on Google Scholar for research entitled: Cannabidiol in Psychiatry.

A recent and well documented article on the topic of Cannabisiol-based Neurotherapy is the following:

G. M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio and P. Brambilla (2018). 
Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. 
Epidemiology and Psychiatric Sciences, 27, 327335. Cambridge University Press 2018; doi:10.1017/S2045796018000239